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A series of isonuclear oligomycin-resistant mutants of Saccharomyces cerevisiae carrying mutations in the 
mitochondrial o il gene has been studied. DNA sequence analysis of this gene has been used to define the 
amino acid substitutions in subunit 9 of the mitochondrial ATPase complex. A domain of amino acids in- 
volved in oligomycin resistance can be recognized which encompasses residues in each of the two hydro- 
phobic portions of the subunit 9 polypeptide that are thought to span the inner mitochondrial membrane. 
Certain amino acid substitutions also confer cross-resistance to venturicidin: these residues define an inner 
domain for venturicidin resistance. The expression of venturicidin resistance resulting from one particular 
substitution is modulated by nuclear genetic factors. 
Proteolipid Mitochondrial ATPase complex 
(Yeast) Drug-resistance domain 
1. INTRODUCTION 
The olil gene in mitochondrial DNA (mtDNA) 
of Saccharomyces cerevisiae codes for subunit 9 of 
the mitochondrial ATPase complex (mtATPase) 
[1,2]. Subunit 9 is a 76 amino acid proteolipid 
which plays a key role in the proton-translocating 
activity of the mtATPase; this subunit can be 
covalently bound by DCCD. The ofil gene was in- 
itially identified through the analysis of oliR 
mutants. In previous work, direct amino acid se- 
quencing of subunit 9 from spontaneously arising 
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phenotype); TID, 3-(trifluoromethyl)-3-(m-[‘251]- 
phenyl)diazirin 
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oliR mutants revealed 3 possible amino acid sub- 
stitutions [3]. These lie in the C-terminal portion of 
the protein, in close proximity to Glu5a where 
DCCD binds [4]. 
We recently studied [5] a set of oliR mutants, 
from diverse parent strains, that had previously 
been subjected to extensive genetic analysis (in- 
cluding tests on cross-resistance to venturicidin). A 
key finding of our DNA sequencing analysis was 
the identification of amino acid substitutions at 
Gly23 (to Ah or Cys) in the N-terminal portion Of 
subunit 9 that lead to resistance to both oligomycin 
and venturicidin. A domain of resistance to these 
drugs could thus be envisaged to encompass amino 
acids in both the N-terminal and C-terminal por- 
tions of subunit 9 [5]. In this view, the S. cerevisiae 
proteolipid folds into a hairpin structure that spans 
the membrane, as suggested for the homologous 
proteolipid subunits of other mitochondrial and 
bacterial ATPase complexes [6]. Differentiation of 
the resistance domains in yeast for oligomycin and 
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venturicidin was made possible by the identifica- 
tion of those amino acid substitutions leading to 
oligomycin resistance without cross-resistance to 
venturicidin [5]. 
In this work, a further series of 7 oliR mutants, 
all isolated from a common parent strain, have 
been studied by DNA sequence analysis of the olil 
gene. We describe additional amino acid substitu- 
tions in subunit 9 leading to the oliR phenotype. 
Other consequences of the mutations, including 
the degree of cross-resistance to venturicidin, are 
appraised. 
2. MATERIALS AND METHODS 
2.1. Strains 
S. cerevisiae J69-1B MATa adel his5 [rho’], 
L410 MATa: Ural his5 [rho+] (both from the 
Monash collection) and 8960- 14B MA Ta ura3 leu2 
karl-I [rho+] (from G.R. Fink) are oligomycin- 
sensitive strains. The rho” derivatives (devoid of 
mtDNA) of each of these rho+ parent strains were 
derived by ethidium bromide treatment [7]. 
2.2. Methods 
Growth of strains and genetic analyses [S], muta- 
genesis with MnC12 [9], cytoduction of mtDNA in- 
volving karl mutants with rho+ donors and rho” 
recipients [lo], and nucleotide sequence determina- 
tion of the olil gene [5] were carried out as 
previously described. 
3. RESULTS AND DISCUSSION 
3.1. Characterization of oligomycin-resistant 
mutants 
A series of oliR mutants was isolated from strain 
J69-1B following mutagenesis with MnC12. The 
mutant isolates were classified initially into 2 
groups: those showing mitochondrial or nuclear 
inheritance [8] of the oliR phenotype (more than 
95% of these isolates were mitochondrial by the 
applied criteria of mitotic segregation and ethidium 
bromide elimination of mtDNA). The mitochon- 
drial mutants were further classified as ofil or oli2 
mutants by mating to reference oliR strains carry- 
ing mutations at the olil or oli2 loci. Some mutants 
showed tight linkage to oli2 markers (less than 5% 
recombination) and were classified as oli2; the ma- 
jority showed linkage to ofil alleles in recombina- 
tion tests, but little linkage to oli2. The latter 
mutants were further classified by tests of their 
cross-resistance to venturicidin and their tempera- 
ture sensitivity; 7 putative olil mutants with 
various phenotypes (table 1) were selected for fur- 
ther study. Each such mutant was mated to petite 
23-3 carrying the olil gene (that would confer the 
oli’ phenotype) [ 111; in all cases significant segre- 
Table 1 
Nucleotide changes in olil gene and resulting amino acid substitutions in oligomycin-resistant strains 
Isolate 
number 
Phenotype DNA 
sequence 
number 
Nucleotide 
change 
Codon 
number 
Codon 
change 
Amino 
acid 
change 
Allele 
0811 OR VR’ 
0812 OR vs 
0814 OR vs 
0821 OR vs 
0850 OR VRb 
0807 OR VRC 
0851 OR VR’ 
+ 67 
+ 67 
+ 159 
+159 
+ 166 
+ 192 
+ 192 
G-T 
G-A 
A-+T 
A-T 
G-+A 
C-+A 
C-A 
23 GGU+UGU Gly-Cys 
23 GGU+AGU Gly + Ser 
53 UUA+UUU Leu+Phe 
53 UUA+UUU Leu-+Phe 
56 GCC -+ ACC Ala+Thr 
64 UUC+UUA Phe+Leu 
64 UUC*UUA Phe+Leu 
olil-704 
olil- 705 
olil-706 
olil-706 
olil-707 
olil-708 
olil-708 
Phenotypes: OR, oligomycin-resistant; VR or V’, venturicidin-resistant or -sensitive, respectively (with the following 
qualifications: %trongly cold-sensitive, i.e. very little growth on non-fermentable substrates at 18°C; bweakly cold- 
sensitive; ‘weakly cold-sensitive with an ambiguous cross-resistance to venturicidin). Allele numbers are assigned as in 
[5], except that identical mutations in the isogenic strains analyzed here are given the same allele number. Note that 
as mutants were selected for analysis because of their different phenotypes, the distribution of mutations in this table 
does not reflect their frequency of occurrence 
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gation of rho+ oli’ diploids was observed, thus 
confirming the assignment of the oliR mutation to 
the olil region. 
3.2. Sequence changes in oligomycin-resistant 
mutants 
The sequence of the olil gene in each of the 7 
mutants was determined. The single nucleotide 
changes observed relative to the wild-type se- 
quence, together with the consequent amino acid 
substitutions, are shown in table 1. Two isolates 
(0811 and 0812) carry substitutions at amino acid 
residue 23. In the case of mutant 08 11 (Glyz3-C~~) 
the mutation is identical to one previously iden- 
tified in strain L748 [5]; the cold-sensitive pheno- 
type and other properties of these 2 mutants, in- 
cluding the reduced mobility of subunit 9 on poly- 
acrylamide gels [12], are very similar. The other 
mutant (0812) in which amino acid 23 is altered 
(Gb23 + Ser), represents a second case of a 
substitution at this position leading to oligomycin 
and venturicidin resistance with no concomitant 
temperature sensitivity. We previously identified 
[5] a Glyz3+Ala substitution conferring similar 
properties. It is of interest hat the radical substitu- 
tion Gly23+Asp identified in mit- strain lSB-2 
leads to non-functional subunit 9 [13]. 
The other substitutions in oliR mutants lie in the 
C-terminal arm of subunit 9. Two mutants 0814 
and 0821 carry one of the most commonly en- 
countered substitutions in subunit 9, namely 
Leu53jPhe [1,2,5,14]. ThesubstitutionAlase-rThr 
in mutant 0850 has not been previously recognized. 
This mutation confers oligomycin resistance with a 
strong cross-resistance to venturicidin. The final 2 
mutants 0807 and 0851 carry the same substitution 
Table 2 
Oligomycin and venturicidin phenotype in mutant strains and derived cytoductants 
Group Strain constitution Phenotype 
Nucleus Mitochondrion OLI(4) VEN( 1) VEN(5) 
(A) Mutants L4100 L4100 R R S/R 
J69-1B 085 1 R S/R S/R 
J69-1B 0807 R S/R S/R 
J69-1B 0814 R S S 
J69-1B 0850 R R R 
(B) Cytoductants L410 L4100 R R R 
L410 0851* R R R 
J69-1B L4100 R S/R S/R 
J69-1B 0851” R S/R S/R 
8960-14B L4100b R R S/R 
8960-14B 0851asb R R S/R 
a Cytoductants derived from mutant 0807 show same phenotype as those from 0851 
b Cytoductants with the 8960-14B nuclear background show reduced growth on control 
YEPE plates (no drugs) relative to rho+ strains with the other nuclear backgrounds tested 
here 
Cytoductants were made by crossing mutants to the rho” derivative of strain 8960-14B (karl) 
then selecting Leu+ Ura+ rho+ haploid clones. These primary cytoductants were then crossed 
back to rho” derivatives of strains L410 or J69-lB, selecting haploid rho+ clones with the ap- 
propriate auxotropic requirements. Drug resistance was tested by dropping cell suspensions 
onto YEPE plates [8] with the following concentrations of drugs: OLI(4), oligomycin 4 
pg/ml; VEN( l), venturicidin 1 ,ug/ml; VEN(S), venturicidin 5 rg/ml. Phenotypes were scored 
after 7 days at 28’C as follows: R, unambiguous resistance (similar growth to control spots 
plated in absence of drugs); S, unambiguous sensitivity (no growth on drug plate); S/R, am- 
biguous phenotype (detectable growth, but inhibited relative to control) 
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(Phti+Leu). In this case the venturicidin 
resistance is barely detectable. Precisely the same 
mutation has been identified in strain L4100 [5]; in 
that case an appreciable resistance to venturicidin 
was observed. It was important to resolve this 
anomaly as residue 64 lies near the boundary of the 
domain of venturicidin resistance that we have 
proposed [5]. The genetic analysis described in sec- 
tion 3.3 reveals the influence of nuclear genes on 
the expression of venturicidin resistance at residue 
64. 
3.3. Expression of venturicidin resistance can be 
subject to nuclear influence 
Table 2A indicates phenotypes of the 3 strains 
(L4100, 0851, 0807) carrying the mutation 
Phecd-rLeu. As noted in [5], strain L4100 is resis- 
tant to venturicidin at 1 /cg/ml, but shows little 
resistance to this drug at 5 pg/ml. By contrast 
mutants 0851 and 0807 show little or no resistance 
to venturicidin even at 1 pg/ml. For comparative 
purposes, the behaviour of 2 other oliR mutants 
derived from strain J69-1B is shown in table 2A, 
namely 0814 and 0850 which show, respectively, 
complete sensitivity or strong resistance to ven- 
turicidin. 
The technique of cytoduction, utilizing crosses 
involving haploids carrying the karl-2 mutation 
that prevents efficient nuclear fusion [15], enables 
mitochondrial genomes to be transferred to speci- 
fied nuclear backgrounds in a systematic way [lo]. 
Table 2B indicates the phenotypes of cytoductants 
constructed so as to place the mtDNA genomes of 
mutants L4100 and 0851 in common nuclear back- 
grounds, namely those of strains J69-lB, L410 and 
8960-14B (the last-named is the karl mutant strain 
used in the cytoduction manipulations). It is clear 
from the results that the critical determinant of 
venturicidin resistance of the Phea+Leu mutants 
is the nuclear background in which the mtDNA is 
resident. For example, mtDNA from mutant 0851 
in the L410 background now elicits marked resist- 
ance to venturicidin even at 5 /g/ml, indistinguish- 
able from that of L4100 mtDNA cytoduced into 
the same L410 nuclear background. Furthermore, 
when L4100 mtDNA is placed in the J69-1B 
nuclear background the venturicidin resistance 
pattern (now very weak) corresponds exactly to 
that of a cytoductant carrying 0851 mtDNA in- 
troduced into the J69-1B background (note that 
162 
this pattern mimics exactly that of the original mu- 
tant 0851). Although the growth rate on non- 
fermentable substrates of cytoductants in the 
8960-14B nuclear background is reduced relative to 
that of other strains (donors, or cytoductants in 
other backgrounds), a similar pattern of resistance 
to venturicidin conferred by mtDNA genomes of 
both L4100 and 0851 is observed (table 2B). 
3.4. Domains in subunit 9 for oligomycin 
and venturicidin resistance 
A compilation is made in fig.1 of all reported 
t 
-S- 
42 
(I ;: 
coo- 
NH; 
Fig. 1. Domains of oligomycin and venturicidin resistance 
in yeast mtATPase subunit 9. The subunit 9 polypeptide 
is represented in a hairpin configuration [5,11], with the 
2 membrane-spanning domains indicated as vertical 
straight lines. Amino acids relevant to drug resistance 
domains are indicated here by residue number; using 
single-letter code, the wild-type residues and substitu- 
tions in sequenced mutants ([3,5]; this paper) are shown. 
The venturicidin-resistance domain (VEN) overlaps with 
and lies entirely within the oligomycin-resistance domain 
(OLD. Also indicated are the positions of Glu59 (the 
DCCD-binding site) and Ser42 which lies in the 
hydrophilic loop, but which is not thought to lie directly 
in the oligomycin-binding domain (51. 
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amino acid substitutions in mtATPase subunit 9 of 
S. cerevisiae leading to oligomycin or venturicidin 
resistance, Domains of amino acid considered to 
be involved in the binding sites for these 2 drugs [5] 
are indicated. The newly sequenced mutants fall 
largely within these domains as previously iden- 
tified, with the extension that the venturicidin do- 
main now inciudes residue 56. A further substitu- 
tion at residue 23 (Gly-rSer) has also been 
identified. 
Recently, Sebald et al. [16f have carried out 
chemical modification studies on ~e~~os~o~~ 
crassc~ subunit 9 using a lipid-soluble carbene 
(TID) as a photoaffinity probe [ 171. About 10 
residues cattered through the 2 hydrophobic stems 
of the polypeptide were found to be labelled. The 
chemical modification of those residues around 
Glue5 (DCCD-binding site in the ~~~os~or# pep- 
tide) was blocked by oligomycin, leading to the 
conclusion that certain residues in the region 
Serrr-Phero (corresponding to yeast residues 
Prodg-PheM) are involved in binding oligomycin. 
This chemically defined binding domain corre- 
sponds broadly to the resistance domain on the C- 
terminal stem shown in fig.1. Surprisingly, oligo- 
mycin was not found to protect any residues in the 
N-terminal stem, particularly those in the vicinity 
of residues equivalent to yeast Gly23. This may 
reflect the failure of TID to bind covalently to 
amino acids in the putative oligomycin-binding do- 
main on the N-terminal stem. Nevertheless, it can- 
not yet be excluded that Glyz3 does not participate 
directly in binding oligomycin and that substitu- 
tions at this position lead to the oliR phenotype by 
interactions that distort the conformation of the 
binding domain on the C-terminal stem. 
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